CLINICAL TRIAL: A5235 - MINOCYCLINE IN THE TREATMENT OF HIV-ASSOCIATED COGNITIVE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: To examine whether Minocycline treatment for 24 weeks improves HIV-associated cognitive impairment. Participants: 100 subjects (50 subjects per arm) who are HIV-1 infected and are on a stable antiretroviral regimen with progressive neurocognitive impairment. Procedures (methods): Step 1: Double-Blind At entry, subjects will be randomized to one of two arms in the 24-week double-blind phase. Arm 1: Minocycline 100 mg, orally every 12 hours. Arm 2: Matching placebo, orally every 12 hours. Step 2: Open-Label Subjects who complete the 24-week double-blind phase (Step 1) will be offered the option to enter Step 2 and participate in the open-label minocycline phase for an additional 24 weeks. The open-label participation is optional. Minocycline 100 mg, orally every 12 hours.